BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
Authors
Keywords
-
Journal
Oncogenesis
Volume 9, Issue 3, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-11
DOI
10.1038/s41389-020-0218-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma
- (2018) Jingyuan Wang et al. CANCER LETTERS
- Transcription factors orchestrate dynamic interplay between genome topology and gene regulation during cell reprogramming
- (2018) Ralph Stadhouders et al. NATURE GENETICS
- BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis
- (2018) Xingchen Dong et al. Cell Death & Disease
- Identification of Nidogen 1 as a lung metastasis protein through secretome analysis
- (2017) Maša Alečković et al. GENES & DEVELOPMENT
- Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC
- (2017) Sander B. Frank et al. JOURNAL OF CELL SCIENCE
- BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC
- (2017) Mingchen Ba et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The interplay of epigenetic marks during stem cell differentiation and development
- (2017) Yaser Atlasi et al. NATURE REVIEWS GENETICS
- RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN
- (2017) Valentina Sancisi et al. NUCLEIC ACIDS RESEARCH
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- (2016) Mark L. McCleland et al. JOURNAL OF CLINICAL INVESTIGATION
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution
- (2016) M Ryan Corces et al. NATURE GENETICS
- BET inhibition as a new strategy for the treatment of gastric cancer
- (2016) Raquel C. Montenegro et al. Oncotarget
- RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression
- (2015) Karine A. Cohen-Solal et al. Molecular Cancer
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma
- (2014) Dhong Hyun Lee et al. INTERNATIONAL JOURNAL OF CANCER
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
- (2014) Tomohiko Kanno et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
- (2013) Jason D Buenrostro et al. NATURE METHODS
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives
- (2012) Federico Andreoli et al. CURRENT PHARMACEUTICAL DESIGN
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started